Last10K.com

Adaptimmune Therapeutics Plc (ADAP) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021

Adaptimmune Therapeutics Plc

CIK: 1621227 Ticker: ADAP
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2021
Mar. 11, 2022
Jun. 30, 2021
Cover [Abstract]   
Document Type10-K  
Document Annual Reporttrue  
Document Period End DateDec. 31, 2021  
Document Transition Reportfalse  
Entity File Number001-37368  
Entity Registrant NameADAPTIMMUNE THERAPEUTICS PLC  
Entity Incorporation, State or Country CodeX0  
Entity Address, Address Line One60 Jubilee Avenue, Milton Park  
Entity Address, City or TownAbingdon, Oxfordshire   
Entity Address, CountryGB  
Entity Address, Postal Zip CodeOX14 4RX  
City Area Code44  
Entity Tax Identification Number00-0000000  
Title of 12(b) SecurityAmerican Depositary Shares, each representing   
Local Phone Number1235 430000  
Security Exchange NameNASDAQ  
Entity Well-known Seasoned IssuerYes  
Entity Voluntary FilersNo  
Entity Current Reporting StatusYes  
Entity Interactive Data CurrentYes  
Entity Filer CategoryLarge Accelerated Filer  
Entity Small Businessfalse  
Entity Emerging Growth Companyfalse  
ICFR Auditor Attestation Flagtrue  
Entity Shell Companyfalse  
Trading SymbolADAP  
Entity Common Stock, Shares Outstanding 940,393,818 
Entity Public Float  $ 583,895,832
Entity Central Index Key0001621227  
Current Fiscal Year End Date--12-31  
Document Fiscal Year Focus2021  
Document Fiscal Period FocusFY  
Amendment Flagfalse  
Auditor NameKPMG LLP  
Auditor Firm ID1118  
Auditor LocationReading, United Kingdom  

View differences made from one year to another to evaluate Adaptimmune Therapeutics Plc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adaptimmune Therapeutics Plc.

Continue

Assess how Adaptimmune Therapeutics Plc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Adaptimmune Therapeutics Plc's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Other
Filter Subcategory:
All
Shares
Expense
Income
Product
Earnings
Geography
Cash Flow
Other
Inside Adaptimmune Therapeutics Plc's 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Change In Equity
Consolidated Statements Of Comprehensive Loss
Consolidated Statements Of Comprehensive Loss (Parenthetical)
Consolidated Statements Of Operations
Accrued Expenses And Other Current Liabilities
Accrued Expenses And Other Current Liabilities (Details)
Accrued Expenses And Other Current Liabilities (Tables)
Contingencies And Commitments
Contingencies And Commitments - Capital Commitments (Details)
Contingencies And Commitments - Clinical Trials And Contract Manufacturing Commitments (Details)
Contingencies And Commitments - Collaborations And License Agreements (Details)
Financial Instruments
Financial Instruments (Tables)
Financial Instruments - Cash Equivalents And Short-Term Deposits (Details)
Financial Instruments - Collaboration And License Agreement (Details)
Financial Instruments - Fair Value Of Assets And Liabilities (Details)
Financial Instruments - Foreign Exchange Risk (Details)
General
General (Details)
Geographic Information
Geographic Information (Tables)
Geographic Information - Major Customers (Details)
Geographic Information - Operations By Geographic Area - Long-Lived Assets (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Change In Tax Rate (Details)
Income Taxes - Change In Valuation Allowance (Details)
Income Taxes - Change In Valuation Allowance Narrative (Details)
Income Taxes - Components Of Income Tax Expense (Benefit) (Details)
Income Taxes - Loss Before Income Taxes (Details)
Income Taxes - Reconciliation Of Deferred Tax Assets And Liabilities (Details)
Income Taxes - Reconciliation Of Effective Tax Rate (Details)
Income Taxes - Tax Rates (Details)
Income Taxes - Unrecognized Tax Benefits (Details)
Intangible Assets, Net
Intangible Assets, Net (Tables)
Intangible Assets, Net - Aggregate Amortization Expense (Details)
Intangible Assets, Net - Amortization Expense (Details)
Intangible Assets, Net - Tabular Disclosure (Details)
Operating Leases
Operating Leases (Tables)
Operating Leases - Lease Cost (Details)
Operating Leases - Maturities (Details)
Other Current Assets
Other Current Assets (Details)
Other Current Assets (Tables)
Property, Plant And Equipment, Net
Property, Plant And Equipment, Net (Tables)
Property, Plant And Equipment, Net - Depreciation Expense (Details)
Property, Plant And Equipment, Net - Schedule Of Property And Equipment (Details)
Revenue
Revenue (Tables)
Revenue - Collaboration Agreement - The Astellas Collaboration Agreement (Details)
Revenue - Collaboration Agreement - The Genentech Collaboration And License Agreement (Details)
Revenue - Collaboration Agreement - The Gsk Collaboration And License Agreement (Details)
Revenue - Revenue From Contracts With Customers (Details)
Share Based Compensation - Option Activity (Details)
Share Based Compensation - Options Exercised (Details)
Share Based Compensation - Stock Options Outstanding (Details)
Share Based Compensation - Unrecognized Compensation Cost (Details)
Share-Based Compensation
Share-Based Compensation (Tables)
Share-Based Compensation - Fair Value Assumptions (Details)
Share-Based Compensation - Option Plans (Details)
Share-Based Compensation - Options (Details)
Share-Based Compensation - Share-Based Compensation Expense (Details)
Stockholders' Equity
Stockholders' Equity - Ordinary Shares (Details)
Stockholders' Equity - Underwritten Public Offering And Registered Direct Offering (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Accounts Receivable (Details)
Summary Of Significant Accounting Policies - Antidilutive Securities (Details)
Summary Of Significant Accounting Policies - Available-For-Sale Debt Securities (Details)
Summary Of Significant Accounting Policies - Cash, Cash Equivalents And Restricted Cash (Details)
Summary Of Significant Accounting Policies - Changes In Accumulated Other Comprehensive (Loss) Income (Details)
Summary Of Significant Accounting Policies - Foreign Currency (Details)
Summary Of Significant Accounting Policies - Intangibles (Details)
Summary Of Significant Accounting Policies - Interest Income (Details)
Summary Of Significant Accounting Policies - Leases (Details)
Summary Of Significant Accounting Policies - Loss Per Share (Details)
Summary Of Significant Accounting Policies - Options (Details)
Summary Of Significant Accounting Policies - Property, Plant And Equipment (Details)
Summary Of Significant Accounting Policies - Reclassification Out Of Other Comprehensive (Loss) Income (Details)
Summary Of Significant Accounting Policies - Research And Development Expenditure (Details)
Summary Of Significant Accounting Policies - Retirement Benefits (Details)
Summary Of Significant Accounting Policies - Segment Reporting (Details)
Ticker: ADAP
CIK: 1621227
Form Type: 10-K Annual Report
Accession Number: 0001558370-22-003489
Submitted to the SEC: Mon Mar 14 2022 7:16:11 AM EST
Accepted by the SEC: Mon Mar 14 2022
Period: Friday, December 31, 2021
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/adap/0001558370-22-003489.htm